Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EIF2AK2 | P19525 | 2/20 | 1.00 |
| ▸ | MAPK12 | P53778 | 2/20 | 1.00 |
| ▸ | MAPK13 | O15264 | 1/20 | 1.00 |
| ▸ | MAPK11 | Q15759 | 1/20 | 1.00 |
| ▸ | MAPK14 | Q16539 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 8/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 8/20 | 0.45 |
| ▸ | MAPT | P10636 | 6/20 | 0.45 |
| ▸ | CASP1 | P29466 | 5/20 | 0.45 |
| ▸ | CASP7 | P55210 | 5/20 | 0.45 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.45 |
| ▸ | POLB | P06746 | 3/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.45 |
| ▸ | PABPC1 | P11940 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30821077 | 0.80 | EIF2AK2 (0.67) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL8176664 | 0.80 | EIF2AK2 (0.66) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL10806544 | 0.77 | MAPK13 (0.62) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL11120339 | 0.77 | EIF2AK2 (0.62) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL10349467 | 0.72 | EIF2AK2 (0.56) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL8172006 | 0.71 | EIF2AK2 (0.54) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL4846358 | 0.70 | EIF2AK2 (0.53) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL9286184 | 0.70 | EIF2AK2 (0.53) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL18122168 | 0.69 | MAPK13 (0.53) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 | |
| SCHEMBL25255273 | 0.68 | MAPK13 (0.51) | EIF2AK2MAPK12MAPK13MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190153394-A1 | Generation of pancreatic endoderm from pluripotent stem cells using small molecules | TAKARA BIO EUROPE SAS (FR) | 2019-05-23 | — | — | US | disclosed |
| US-10221392-B2 | Generation of pancreatic endoderm from pluripotent stem cells using small molecules | NOVO NORDISK A/S (DK) | 2019-03-05 | — | — | US | disclosed |
| US-20170114323-A1 | USES OF KINASE INHIBITORS FOR INDUCING AND MAINTAINING PLURIPOTENCY | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2017-04-27 | — | — | US | disclosed |
| US-20160326495-A1 | Generation of Pancreatic Endoderm from Pluripotent Stem Cells using Small Molecules | TAKARA BIO EUROPE SAS (FR) | 2016-11-10 | — | — | US | disclosed |
| US-20160326495-A1 | Generation of Pancreatic Endoderm from Pluripotent Stem Cells using Small Molecules | TAKARA BIO EUROPE SAS (FR) | 2016-11-10 | — | — | US | disclosed |
| US-20160250190-A1 | N-METHYL PYRAZOLOANTHRONE FOR TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-01 | — | — | US | disclosed |
| US-20160250190-A1 | N-METHYL PYRAZOLOANTHRONE FOR TREATMENT OF CANCER | THE GENERAL HOSPITAL CORPORATION (US) | 2016-09-01 | — | — | US | disclosed |
| US-20150247123-A1 | Generation of pancreatic endoderm from Pluripotent Stem cells using small molecules | TAKARA BIO EUROPE AB (SE) | 2015-09-03 | — | — | US | disclosed |
| US-20150247123-A1 | Generation of pancreatic endoderm from Pluripotent Stem cells using small molecules | TAKARA BIO EUROPE AB (SE) | 2015-09-03 | — | — | US | disclosed |
| WO-2014033322-A1 | GENERATION OF PANCREATIC ENDODERM FROM PLURIPOTENT STEM CELLS USING SMALL MOLECULES | NOVO NORDISK A/S (DK) | 2014-03-06 | — | — | WO | disclosed |
| WO-2008091925-A2 | TREATMENT OF AORTIC DISSECTION OR ANEURYSM | COOK INCORPORATED (US) | 2008-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160250190-A1 | N-METHYL PYRAZOLOANTHRONE FOR TREATMENT OF CANCER | CSNK1A1, CSNK1G1, CSNK1A1L | EIF2AK2 1572/4885MAPK12 955/4885MAPK13 786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.